Comprehensive Diagnostics Genoptix offers a broad precision oncology testing portfolio spanning pathology to next-generation assays, enabling hospitals to consolidate testing with a single vendor and unlock bundled service opportunities for hematologic and solid-tumor programs.

NeoGenomics Network As a NeoGenomics company, Genoptix can leverage an established distribution network and cross-selling capabilities to accelerate adoption of new tests and expand reach within oncology centers.

CML Monitoring Lead The FDA-authorized BCR-ABL MRDx TFR Monitoring Test for CML provides a high-value offering to hematology clinics managing Tasigna-treated patients, presenting a clear entry point for workflow integrations and recurring testing revenue.

Genome Mapping Focus Adopting Saphyr for hematologic indications demonstrates a commitment to innovative cytogenomics, creating partnerships with research-focused hospitals and cancer centers pursuing advanced diagnostic capabilities.

Strategic Growth Position Longstanding oncology diagnostics expertise and a large patient-diagnosed base support pursuing mid-to-large health system collaborations, standardized testing menus, and data-driven reporting to differentiate in a competitive market.